A comparison of linezolid with glycopeptides in severe MRSA pneumonia

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 8, 2009, Pages 951-955

  Abunasser, Jafar ^a   Metersky, Mark L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Linezolid; Methicillin resistant Staphylococcus aureus; Nosocomial pneumonia; Teicoplanin; Vancomycin; Ventilator associated pneumonia

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; GRAM POSITIVE INFECTION; HISTOPATHOLOGY; LUNG LAVAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PIGLET; SURVIVAL;

EID: 70350576670     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.78     Document Type: Article

References (35)

1. Luna CM, Bruno DA, García-Morato J et al. Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets. Chest 135(6), 1564-1571 (2009).
2. Baughman RP, Tapson V, McIvor A. The diagnosis and treatment challenges in nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 33(2), 131-139 (1999). (Pubitemid 29115042)
3. Textbook of Pulmonary Diseases. Baum GL, Crapo JD, Celli BR, Karlinsky JB (Eds). Lippincott-Raven, PA, USA (1998).
4. Bergogne-Berezin E, Decre D, Joly-Guillou ML. Opportunistic nosocomial multiply resistant bacterial infections - their treatment and prevention. J. Antimicrob. Chemother. 32(Suppl. A), 39-47 (1993). (Pubitemid 23244708)
5. George DL. Epidemiology of nosocomial pneumonia in intensive care unit patients. Clin. Chest Med. 16(1), 29-44 (1995).
6. Greenaway CA, Embil J, Orr PH, McLeod J, Dyck B, Nicolle LE. Nosocomial pneumonia on general medical and surgical wards in a tertiary-care hospital. Infect. Control Hosp. Epidemiol.18(11), 749-756 (1997).
7. Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL. Nosocomial pneumonia in Medicare patients. Hospital costs and reimbursement patterns under the prospective payment system. Arch. Intern. Med. 151(6), 1109-1114 (1991).
8. Craig CP, Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am. J. Infect. Control. 12(4), 233-238 (1984).
9. American Thoracic Society, IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
10. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol. 21(8), 510-515 (2000).
11. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274(8), 639-644 (1995).
12. Panlilio AL, Culver DH, Gaynes RP et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect. Control Hosp. Epidemiol.13(10), 582-586 (1992).
13. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 22(5), 387-394 (1996).
14. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115(2), 462-474 (1999). (Pubitemid 29083057)
15. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111(3), 676-685 (1997). (Pubitemid 27132946)
16. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States. Morbl. Mortal. Wkly. Rep. 46 (35), 813-815 (1997).
17. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40(1), 135-136 (1997).
18. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. 39(3), 673-679 (1996).
19. Matassova NB, Rodnina MV, Endermann R et al. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 5(7), 939-946 (1999). (Pubitemid 29321073)
20. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40(4), 839-845 (1996).
21. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18(3), 456-462 (1998).
22. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob. Agents Chemother. 40(7), 1745-1747 (1996).
23. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob. Agents Chemother. 41(2), 465-467 (1997).
24. Wilcox MH, Tack KJ, Bouza E et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a Phase 3 study. Clin. Infect. Dis. 48(2), 203-212 (2009).
25. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32(3), 402-412 (2001).
26. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25(3), 980-992 (2003).
27. Kalil AC, Puumala SE, Stoner J. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 125(6), 2370-2371 (2004). (Pubitemid 38788219)
28. Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 126(1), 314-315; author reply 315-316 (2004).
29. Marquette CH, Wermert D, Wallet F, Copin MC, Tonnel AB. Characterization of an animal model of ventilator-acquired pneumonia. Chest 115(1), 200-209 (1999). (Pubitemid 29047076)
30. Millo JL, Schultz MJ, Williams C et al. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med. 30(1), 68-74 (2004).
31. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit. Care Med. 27(9), 1745-1753 (1999). (Pubitemid 29455099)
32. Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother. 38(5), 865-869 (1996). (Pubitemid 26413723)
33. Conte HA, Chen YT, Mehal W, Scinto JD, Quagliarello VJ. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am. J. Med. 106(1), 20-28 (1999). (Pubitemid 29077138)
34. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J. Antimicrob. Chemother. 51(6), 1431-1434 (2003).
35. Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother. 38(11), 2643-2647 (1994). (Pubitemid 24332600)